NEW YORK – LGC Clinical Diagnostics on Tuesday announced a partnership with AccuGenomics to jointly develop quality control materials for next-generation sequencing tests.
Financial terms of the codevelopment agreement were not disclosed.
The collaboration will make use of LGC’s expertise in quality control and AccuGenomics’ NGS monitoring technologies. The goal is to develop accurate and reliable molecular diagnostics and quality control materials for cancer NGS testing as well as custom reference materials for NGS assay validation. Read more in the full Press Release